Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

on activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the SEC. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three months ended March 31, 2008 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Mass (PRWEB) January 21, 2015 Cambridge Semantics, ... Web technology, today announced that 2014 was a record-breaking year ... the capabilities of the Anzo Smart Data Platform and our ... and utilize insights from diverse data which led to record ...
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... , , , ... (GSK) (NYSE: GSK ) today announced that it has completed ... share capital of Stiefel for a cash consideration of $2.9 billion. ... of the agreement, GSK may be obligated to make additional cash payments ...
... ... SBIR grants from the National Institutes of Health to develop original in silico technologies to ... rates of DNA and RNA experiments. , ... (Vocus) July 22, 2009 -- DNA Software, Inc. has been awarded three Fast ...
... , , PHILADELPHIA and LONDON, ... and often cited compendium of pharmaceutical research and development statistics, the ... year,s Factbook offers extended content including patent information and ... "The R&D Factbook provides the data that ...
Cached Biology Technology:GlaxoSmithKline Completes Acquisition of Stiefel 2DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies 2DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies 3DNA Software, Inc. Awarded $2.5 M in NIH Funding to Develop Pioneering Nucleic Acid-based Technologies 4Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook 2
(Date:12/19/2014)... Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced the addition ... Systems Market" report to their offering. ... security market is estimated to grow at a CAGR of ... a larger share in this market, Canada ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... an Applera Corporation business, today announced the introduction ... Provider Program, a new program for service providers ... solution for gene expression analysis, including the highly ... and gold-standard TaqMan® Gene Expression Assays for target ...
... an organization dedicated to humane alternatives to the use of ... your own that requires using animals as part of the ... Physicians Committee for Responsible Medicine, you invent your own test. ... has developed the world's first cruelty-free insulin assay, a test ...
... today that they have entered into a non-exclusive ... customers with new software solutions for GeneChip(R) data ... develop a new software package for Affymetrix, ArrayAssist(R) ... statistical analysis solution of Affymetrix gene expression microarrays. ...
Cached Biology News:Harnessing microbes, one by one, to build a better nanoworld 2PCRM develops world's first cruelty-free insulin assay 2Affymetrix and Stratagene Announce Strategic Software Alliance 2
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (C7046) ... assistance. Mfr Desig: Corning ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... ® Ek Adaptor encodes a T7 ... site (rbs), ATG translation initation codon, and ... is a small epitope tag (11 aa) ... target protein with T7•Tag Monoclonal Antibody and ...
Biology Products: